Organon & Co | OGN - Sales Revenues

Stock Price
13.18
Daily Change
1.92 17.01%
Monthly
131.14%
Yearly
3.33%
Q2 Forecast
11.02

Organon & Co reported $1.51B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Celltrion KRW 1.33T 0 Mar/2026
Cspc Pharmaceutical CNY 6.11B 502.75M Dec/2025
Deva Holding AS TRY 2.32B 418.58M Sep/2023
Dianthus Therapeutics USD 284K 112K Dec/2025
Divis Laboratories Ltd INR 26.04B 1.11B Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
Glaxosmithkline GBP 11.46B 59.16M Dec/2025
Kangmei Pharma CNY 1.37B 101.16M Sep/2025
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
Laboratorios Farma EUR 448.66M 67.82M Dec/2023
Medical Developments International AUD 21.57M 12.04M Dec/2025
Merck USD 16.4B 880M Dec/2025
Neuren Pharmaceuticals AUD 42.24M 28.1M Dec/2025
Novartis USD 13.86B 498M Dec/2025
Organigram Holdings CAD 63.54M 16.52M Dec/2025
Organon & Co USD 1.51B 90M Dec/2025
Pharma Mar EUR 90.2M 54.5M Dec/2025
Qiagen NV USD 457.38M 6.06M Dec/2025
Sartorius EUR 899.1M 28.5M Mar/2026
Sino Biopharmaceutical CNY 14.26B 3.31B Dec/2025
Tilray USD 217.51M 74.75M Dec/2025
Zealand Pharma A/S 68.91M 19.35M Dec/2025